A TRIAL REFLECTIVE OF THE PATIENTS TYPICALLY SEEN IN YOUR PRACTICE

The first and only Phase III trial for 1L mPC based on a real-world population3

MPACT is the largest multinational trial (861 patients) in the mPC setting
Study Design

The multinational, randomized, Phase III MPACT study compared ABRAXANE + gemcitabine vs gemcitabine alone as first-line treatment in 861 patients with mPC with normal bilirubin and no prior chemotherapy in the metastatic setting. Primary endpoint was OS. ABRAXANE (125 mg/m2) + gemcitabine (1000 mg/m2) was given QW3/4. In the gemcitabine arm, gemcitabine (1000 mg/m2) was given QW7/8 then QW3/4.

  • 1L=first-line; ECOG=Eastern Cooperative Oncology Group; KPS=Karnofsky Performance Status; MPACT=Metastatic Pancreatic Adenocarcinoma Clinical Trial; mPC=metastatic pancreatic cancer; OS=overall survival; PS=performance status.
  • Conversion: KPS to ECOG PS

    UNDERSTANDING THE RELATION BETWEEN
    PERFORMANCE STATUS MEASUREMENTS5-7
    UNDERSTANDING THE RELATION BETWEEN PERFORMANCE STATUS MEASUREMENTS5-7

    Conversion of Karnofsky Performance Status (KPS) to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Eastern Cooperative Oncology Group Performance Status (ECOG PS)
    Eastern Cooperative Oncology Group Performance Status (ECOG PS)

    This proposed conversion scale was constructed empirically from a sample of patients (n=1385) with advanced cancer, including different tumor types. Both KPS and ECOG PS were determined by 7 physicians for each patient. This conversion scale had the highest rate of agreement (75%) observed among all possible scales.7

    CLOSE THE TAB
  • Patients Were Well Balanced Between Treatment Arms

    PATIENTS WERE WELL BALANCED
    BETWEEN TREATMENT ARMS3

    Patient characteristics of the MPACT Study: ABRAXANE + gemcitabine vs gemcitabine Patient characteristics of the MPACT Study: ABRAXANE + gemcitabine vs gemcitabine
    • ULN=upper limit of normal.
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL